Serum levels of specialised pro-resolving molecule pathways are greatly increased in SARS-CoV-2 patients and correlate with markers of the adaptive immune response.

James Turnbull^{1,2,3,a}, Rakesh Jha^{1,2,a}, Catherine A. Ortori², Eleanor Lunt⁴, Patrick J. Tighe³, William L. Irving^{1,3}, Sameer A. Gohir^{1,6}, Dong-Hyun Kim², Ana M. Valdes^{1,5,6}, Alexander W. Tarr^{1,3}, David A. Barrett^{1,2}, Victoria Chapman^{1,3,5}.

¹ NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK

² Centre for Analytical Bioscience, Advanced Materials and Healthcare Technologies Division, School of Pharmacy, University of Nottingham, Nottingham, UK

³ School of Life Sciences, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK

⁴ Department of Health Care for Older People (HCOP), Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, Nottinghamshire NG7 2UH, UK

⁵ Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK

⁶ Academic Rheumatology, University of Nottingham, Nottingham, UK

^a Joint First Author

Correspondence: Professor Victoria Chapman, mbzvc@exmail.nottingham.ac.uk

Phone: +44 (0)115 82 30136

School of Life Sciences
University of Nottingham
University Park
Nottingham

medRxiv preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background

Specialised pro-resolution molecules (SPMs) halt the transition to chronic pathogenic inflammation. We aimed to quantify serum levels of pro- and anti-inflammatory bioactive lipids in SARS-CoV-2 patients, and to identify potential relationships with innate responses and clinical outcome.

Methods

Serum from 50 hospital admitted inpatients (22 female, 28 male) with confirmed symptomatic SARS-CoV-2 infection and 94 age and sex matched cohort collected prior to the pandemic, were processed for quantification of bioactive lipids. Anti-nucleocapsid and anti-spike quantitative binding assays were performed.

Results

SARS-CoV-2 serum had significantly higher concentrations of omega-6 derived pro-inflammatory lipids and omega-6 and omega-3 derived SPMs, compared to age and sex matched controls. Levels of SPMs were not markedly altered by age. There were significant positive correlations between SPMs and other bioactive lipids and anti-spike antibody binding. Levels of some SPMs were significantly higher in patients with an anti-spike antibody value >0.5. Levels of linoleic acid (LA) and 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-DHET) were significantly lower in SARS-COV-2 patients who died.

Discussion

SARS-COV-2 infection was associated with a robust activation of the pathways that generate the specialised pro-resolution molecules and other anti-

51 inflammatory bioactive lipids, supporting the future investigation of these
52 pathways which may inform the development of novel treatments.

53 **Key words:** SARS-CoV-2, specialised pro-resolving molecules, immune
54 response, bioactive lipids, anti-nucleocapsid

55

Introduction

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterised by fever and cough, with more severe cases developing acute respiratory distress, acute lung injury, pneumonia, and mortality[1-3]. The higher rates of severe SARS-CoV-2 illness and death are associated with increasing age[4, 5]. SARS-CoV-2 infection is associated with changes in adaptive and innate immunity, including elevated levels of circulating neutrophils and the presence of peripherally derived macrophages in the lungs of severe cases[6, 7], reduced numbers of circulating T cells[8] and robust cytokine responses, which continues after clearance of the virus[9]. SARS-CoV-2 infection is associated with elevated levels of pro-inflammatory cytokines, including IL6, IL1 β , and TNF α [10, 11], however levels of anti-inflammatory cytokines IL4 and IL10 are also elevated[10]. Knowledge of the impact of SARS-CoV-2 infection on the resolution of inflammation pathways will provide crucial new mechanistic insight and potential new avenues for treatment[12-14].

Prostaglandins (PGs) and leukotrienes have essential roles in initiating acute inflammatory responses and the generation of pro-inflammatory cytokines, which sustain chronic inflammatory responses. In concert with these cyclooxygenase (COX) pathways, the lipoxygenase (LOX) pathways produce pro-inflammatory hydroxyeicosatetraenoic acids (HETEs) from arachidonic acid (AA) and hydroxyoctadecadienoic acids (HODEs) from di-homo- γ -linolenic acid (LNA). The active curtailing of inflammatory signalling is essential to restore tissue homeostasis and prevent chronic inflammatory events leading to pathology[15]. Following the initial acute inflammatory phase, specialised pro-resolving molecules (SPMs), derived from key polyunsaturated fatty acids (PUFAs), are generated and

orchestrate the resolution of inflammation by promoting macrophage mediated clearance of cellular debris and counteracting the effects of pro-inflammatory cytokines[15]. The SPMs are derived from omega-6 (ω -6) (LNA, AA) or omega-3 (ω -3) (eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)) substrates via the COX, LOX and cytochrome P450 pathways[15] (SI Figure 1).

The most well characterised SPMs are the resolvins (Rvs), protectins (PDs), and maresins (MaRs), which halt the transition from acute to chronic inflammation preventing pathogenesis[16]. 17(S)-hydroxy Docosahexaenoic acid (17-HDHA), a substrate for the generation of the D series resolvins[15], enhances the adaptive immune response in a preclinical model of influenza[17], both 17-HDHA and resolvin D1 enhance B cell production and promote B cell differentiation towards an antibody secreting phenotype[18]). The epoxyeicosatrienoic acids (EETs), derived from AA via soluble epoxide hydrolase (sEH), also mediate resolution of inflammation [19, 20], down-regulating inflammatory transcription factors such as NF- κ B [21], curtailing the induction of COX2 and production of cytokines[22].

Current knowledge of the consequences of SARS-CoV-2 infection on endogenous levels of SPMs and EETs is in its infancy. Building a comprehensive picture of the impact of SARS-CoV-2 infection upon the serum lipidomic profile will aid understanding of the therapeutic potential of resolution pathways for SARS-COV-2 infection[12, 13, 23]. Our aims were to 1) compare serum levels of a range of SPMs and pro-inflammatory bioactive lipids between patients admitted to hospital with SARS-CoV-2 infection and an age-matched control group, 2) determine the potential relationship between levels of these bioactive lipids and levels of anti-nucleocapsid and anti-spike antibody titre, markers of the production of an adaptive immune response[24] and 3) investigate outcomes following infection.

Methods

Sample Collection and Preparation

Serum samples obtained from 50 inpatients admitted to Nottingham University Hospitals NHS Trust Queen's Medical Centre with symptomatic RT-PCR confirmed SARS-CoV-2 infection were collected as diagnostic specimens for clinical chemistry testing, excess sera were provided anonymously for research purposes. Review by the University of Nottingham's School of Life Sciences Ethical Review Committee deemed the study to not require full ethical review. Approval for use of anonymized clinical data was provided by the NHS Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (ref. 20/HRA/4843). Samples were determined not to be Relevant Materials in line with the Human Tissue Authority. Risk assessments were approved by the UK Health and Safety Executive (ref. CBA1.470.20.1). Serum samples were initially stored at 4°C for 24 h and then inactivated with the WHO-approved protocol (4-hour room temperature incubation with 1% Triton X-100 in PBS) before analysis. Detailed methods on the assessment of the potential effect of the viral deactivation protocol on serum lipid levels are detailed in the supplementary information. Viral genomic sequencing of samples from a subset of these patients was performed as part of the COG-UK consortium[25].

Baseline serum samples from the iBEAT-OA cohort study (n=94) were used as age and sex matched controls[26], which were collected prior to the SARS-CoV-2 pandemic served as a SARS-CoV-2 negative control. As collected pre-pandemic a lack of SARS-CoV-2 infection was not confirmed. The iBEAT-OA cohort had a confirmed diagnosis of osteoarthritis. Ethical approval was obtained from the

Research Ethics Committee (ref: 18/EM/0154) and the Health Research Authority (protocol no: 18021).

Lipidomic Analysis

Serum bioactive lipids were extracted and measured using our published liquid chromatography-mass spectrometry (LC-MS/MS) quantification method for the major classes of pro- and anti-inflammatory lipid molecules, which has been updated to include SPMs and their precursor molecules[27]. 44 bioactive lipids were quantified, detailed methods are in Supplementary Information.

Anti-Nucleocapsid & Anti-Spike Binding Assays

Anti-nucleocapsid and anti-spike quantitative binding assays were performed on serum samples using ELISA following the protocol described by Tighe et al (2020)[24]. Levels of C reactive protein (CRP) were measured in clinical diagnostic tests (mean 172.9 levels ranged from 11-489). The median time between sample collection for CRP measurement and collection of serum for the measurement of bioactive lipids, anti-nucleocapsid and anti-spike antibody binding was 5 days.

Data Analysis

GraphPad Prism (Version 8.2.1) was used. In some cases, patients were stratified into three age groups (<60, 61-74, & >75 years). Groups were assessed for normal distribution using D'Agostino & Pearson test and evaluated for significant changes between groups using Kruskal-Wallis test with multiple comparisons corrected for using Dunn's test. Multivariate analysis using Metaboanalyst 4.0 (<https://www.metaboanalyst.ca/>)[28] including principal component analysis (PCA) was performed. Partial least square discrimination analysis (PLS-DA) was used to identify the lipid mediator clusters. A cross validation analysis was used

154 to validate the PLS-DA model based on accuracy, R² and Q² scores and a
155 permutation test (SI Figure 3). Variable Importance in Projection (VIP) scores
156 greater than 1 were recognized as playing a key role in cluster differentiation (SI
157 Figure 4 & SI Table 1).

158

Results

Characteristics of SARS-CoV-2 infection cohort and clinical features

Serum samples collected from hospital inpatients (22 female, 28 male) with confirmed diagnosis of Sars-CoV-2 (SARS-CoV-2) were studied (SI Table 2). 30 patients recovered and were discharged, 20 died, and 25 spent time in ICU during hospitalisation (SI Table 2).

SARS-CoV-2 serum has a distinct bioactive lipid profile

SARS-CoV-2 serum had high concentrations of ω -6 derived pro-inflammatory lipids (Table 1) and ω -6 and ω -3 derived anti-inflammatory SPM lipids (Table 1), which were significantly increased compared to age and sex matched control serum. In control serum, comparable to the healthy population, many of the anti-inflammatory SPM lipids were not detectable, or present at very low levels[29]. PLS-DA analysis of these lipids identified contributors to the separation between the SARS-CoV-2 and control serum (Figure 1A). 22 lipids from seven classes of lipids had a VIP score >1 and statistically underpinned the separation between the two clusters (SI Figure 4A). Although serum concentrations of the PUFAs (LA, EPA and DHA) were generally not different between the SARS-CoV-2 and control serum (Figure 1B, SI Table 1), concentrations of the down-stream bioactive lipids were markedly increased in SARS-CoV-2 serum (Figure 1B). There were substantially higher levels of the pro-inflammatory molecule PGD₂, and the anti-inflammatory SPMs (17-HDHA, RvD4, LXA4, LXA5), endocannabinoids (2-AG, AEA) and, 11,12-EET in SARS-CoV-2 serum, compared to control serum (Table 1, SI Table 3). Our findings support a profound mobilisation of pro-resolving mediators following SARS-CoV-2 infection.

PLS-DA analysis revealed a clear separation between the SARS-CoV-2 and control serum for the three age groups (SI Figure 2A-C). Overall, the majority of the lipids contributing to the separation between the SARS-CoV-2 and control serum were the same for the three age groups studied (SI Figure 2D). This was confirmed by a univariate analysis (Figure 2, SI Table 4). Overall, the ability to mount a pro-resolution response was not markedly altered by age in our study.

Changes in the flux through enzymatic pathways generating SPMs may provide insight into novel treatments for Sars-CoV-2 infection. Serum levels of DHA and the downstream metabolites, 17-HDHA and 14-HDHA, were correlated in both SARS-CoV-2 and control serum (Figure 3A-B). However, levels of EPA and 18-HEPE were correlated in SARS-CoV-2 serum but not control serum, suggesting a potential upregulation of the E series resolving pathway following infection (Figure 3C).

Serum levels of AA were within a healthy range in the control group[30], but were elevated in SARS-CoV-2 serum across all age groups (SI Figure 5A, Table 1). Levels of the anti-inflammatory EETs and the downstream metabolites (DHETs) are presented both individually and as a ratio to reflect the activity of the sEH pathway (Table 1). The ratio of 11,12-EET:11,12-DHET was significantly increased in SARS-CoV-2 serum, compared to matched control serum (SI Figure 5B). There were some differences in the ratios of 8,9-EET:8,9-DHET and 14,15-EET:14,15-DHET but these were less consistent across the age groups for the two groups (Table 1). In the SARS-CoV-2 serum, levels of AA were correlated with all EETs, whereas in the control serum AA was only correlated with 8,9-EET and 11,12-EET (Figure 4B & 4C). These data suggest changes in the flux through the sEH pathway following SARS-CoV-2 infection, worthy of further future investigation.

Associations between adaptive immune responses to SARS-COV-2 infection and serum levels of bioactive lipids

Anti-SARS-CoV-2 antibody binding to the nucleocapsid protein was interrogated using a reference antigen. Viral sequence data, where available, confirmed that the variants circulating in our cohort were either the Hu-1 strain, or the variant defining the 20B lineage (defined by the spike D614G variant), with no variability in nucleocapsid amino acid sequence[24]. There was a range of levels of anti-nucleocapsid (0.15 to 3.11 OD450) and anti-spike antibody (0.115-3.067 OD450) in the SARS-CoV-2 group. Anti-nucleocapsid data (Table 2) are discussed in SI. Based on the range of anti-spike antibody binding, patients were separated into two groups: low (<0.5 , $n=26$) and high (>0.5 , $n=26$), the subset of patients who died had significantly lower levels of anti-spike antibody binding (SI Figure 6). Levels of 18-HEPE, 17-HDHA, RvD4 and 14,15-EET were significantly higher in patients with an anti-spike antibody value >0.5 (Figure 5). There were statistically significant positive correlations between these lipids and anti-spike antibody binding for the entire group of patients (Table 2).

Analysis of serum levels of bioactive lipids early in the infection and the clinical outcome identified that levels of LA and 5,6-DHET were significantly lower in SARS-CoV-2 infected patients who died, and the ratio of 5,6-EET:5,6-DHET was higher in those patients that died compared to those that survived (SI Table 5).

Discussion

SARS-CoV-2 infection was associated with robust increases in both ω -6 and ω -3 derived bioactive lipids which have well characterized roles in both pro- and anti-inflammatory responses[31]. Significant increases in serum levels of pro-inflammatory lipids included PGE2, TBXB2 and LTB4 and a range of bioactive lipids with well-established roles in dampening down / resolving inflammatory processes were evident in the SARS-CoV-2 group, compared to the age matched control group. Of particular note was the 47-fold increase in levels of the SPM precursor 17-HDHA and the SPMs RvD4 and Mar2, serum levels of which are normally close to, or below, the limits of detection in the healthy population[32]. Substantial increases in levels of some EETs and endocannabinoids also support a concerted anti-inflammatory response via multiple enzymatic pathways following SARS-CoV-2 infection. Our demonstration of a robust activation of the resolution pathways following SARS-CoV-2 infection, irrespective of patient age, points to a complex pathophysiological response which may be amenable to pharmacological intervention and provide new targets for treatment.

There was a broad range of anti-nucleocapsid and anti-spike responses in the SARS-CoV-2 group, indicative of adaptive immune response to infection. Consistent with a larger study, increased anti-spike responses were associated with improved clinical outcome[24]. SARS-CoV-2 patients with higher anti-spike responses (>0.5) had significantly increased levels of a number anti-inflammatory and resolution molecules as well as some pro-inflammatory lipids. The statistically altered bioactive lipids represent clusters of SPMs, lipoxins and EETs which either directly mediate resolution of inflammation or are metabolites in the resolution pathways and are generated by COX, LOX and CYP pathways. Levels of PUFA substrates were not substantially altered by SARS-CoV-2 infection or age, thus it

is unlikely that substrate and therefore diet is major determining factor in the resolution response to SARS-CoV-2 infection. The strong correlations between PUFAs and their downstream SPM pathway metabolites in the SARS-CoV-2 infection group suggests that these enzymatic pathways are upregulated by this infection, particularly evident for the E series pathway. Our findings support future studies of the relationship between the antibody response to SARS-CoV-2 infection, activation of the resolution pathways and clinical outcome in a larger cohort of patients.

Our findings are consistent with the recent report of up-regulation of plasma and serum SPMs and increased expression of related enzymatic pathways in peripheral blood monocyte subsets in 19 patients infected with SARS-CoV-2[33] and findings by Archambault et al (2020)[34]. In addition, increased levels of pro-inflammatory bioactive lipids and anti-inflammatory SPMs, including RvD4, D5, D2, D1 and PDX have been reported in bronchoalveolar lavage from SARS-CoV-2 patient[35]. SPMs are already known to modulate acute lung injury and respiratory distress syndrome[36], supporting these findings following SARS-CoV-2 infection. Antibodies generated by B cells are critical to anti-viral immunity. The D series precursors and resolvins, including 17-HDHA, enhance human B cell antibody production by promoting differentiation towards an anti-body secreting phenotype[18]. In a pre-clinical murine model of influenza immunization, 17-HDHA treatment increased antigen specific antibody responses and protected against live influenza virus infection[17]. These data suggest that a robust generation of 17-HDHA following infection not only acts to counter pro-inflammatory responses but may also facilitate the response of B cells to mount an antibody response. To date there are no studies of the effects of the SPMs on SARS-CoV-2 infection in patients, however, it has been reported that both RvD1

and RvD2 have beneficial effects on inflammatory responses in SARS-CoV-2 infected macrophages[37].

Current evidence suggests that treatments for SARS-CoV-2 infection, alongside vaccinations, will remain a priority in the immediate future. Identification of the critical steps involved in the up-regulation of these anti-inflammatory pathways may be instructive for the development of interventions aimed at dampening the inflammatory response or promoting the clearance of the inflammation arising from SARS-CoV-2 infection. Dexamethasone has been identified as an important treatment to promote recovery from SARS-CoV-2 infection. Dexamethasone has been shown to increase SPM levels in a small number of SARS-CoV-2 infected patients[33], healthy volunteers[38] and in allergic airway inflammation[39]. Future investigation of the potential contribution of SPMs to the beneficial effects of dexamethasone in patients with SARS-CoV-2 infection in a larger cohort will improve further our understanding of the potential mechanisms of action of this treatment.

There are a number of study limitations. Serum samples were collected from patients hospitalised with SARS-CoV-2 for clinical diagnostic tests during the first wave of the pandemic in the UK. Due to the clinical pressures within the system at the time some clinical data, such as BMI, was not collected. It is known that levels of SPMs are decreased with increased BMI, which could potentially contribute to SARS-CoV-2 related morbidities and mortalities[40]. Although we have data relating to whether a patient was admitted to intensive care, clinical decision making was related to multiple factors beyond the severity of the infection and therefore further analysis of potential impact has not been performed. Serum samples were collected within the first few days of hospital admission and represent a snapshot of the anti-nucleocapsid and anti-spike response and the

lipid levels at a point in time. It is important to note that levels of antibodies change over time, however we do not have matched longitudinal data. The anti-nucleocapsid and anti-spike signal provides an indication of the potency of the adaptive immune response following infection. The viral genome sequencing data available for these patients indicated that the nucleocapsid amino acid sequence was completely conserved between infections. While it is possible that there may be mismatches between the antigen used in our assay and the strain of infecting virus that mean that antibodies are present which are undetected by our assay, at the time of sampling there was minimal genetic diversity in UK isolates[www.nextstrain.org]. To mitigate against this, we used ELISAs against two antigens.

In summary, our findings highlight that SARS-CoV-2 infection can lead to very robust activation of the pathways that generate the specialised pro-resolving molecules and other anti-inflammatory bioactive lipids. This new knowledge supports the future investigation of these pathways which may inform the development of novel anti-inflammatory treatments for SARS-CoV-2 infection. Furthermore, these new datasets provide us opportunities to explore further the underlying molecular pathways that regulate the resolution pathways in humans, with the goal of identifying novel approaches for the development of new therapeutics for other infections and chronic inflammatory diseases.

Notes

Author Contributions:

VC, DAB, DHK, & AWT conceived the study, secured the funding, supervised data collection and analysis, and prepared manuscript.

JT, RJ, & CO performed lipidomic analysis of samples.

AWT, PJT, & WLI supplied clinical samples, performed measurement of anti-nucleocapsid and prepared manuscript.

AMV & SAG provided control serum samples.

JT & RJ performed statistical analysis and prepared manuscript.

EL provided clinical insight into data interpretation and prepared manuscript.

All authors reviewed manuscript and had final responsibility for the decision to submit for publication.

Acknowledgements:

The authors thank Professors David Walsh and John Gladman for their advice in preparation of the manuscript. The authors also thank Dr Divyateja Hrushikesh and colleagues from the Queens Medical Centre for providing samples and clinical data.

Disclaimer:

The source of funding had no influence over the design or conduct of the study.

Financial Support:

349 This research was funded by the NIHR Nottingham Biomedical Research Centre.

350 The views expressed are those of the author(s) and not necessarily those of the

351 NHS, the NIHR or the Department of Health and Social Care.

352 **Potential conflicts of interest:** The authors declare no conflicts of interests.

353

References

1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine* **2020**; 8(5): 475-81.
2. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? *The Lancet Respiratory Medicine* **2020**; 8(8): 816-21.
3. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* **2020**; 180(7): 934-43.
4. Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. *PloS one* **2020**; 15(11): e0241824-e.
5. Jayaraj R, Kumarasamy C, Shetty SS, Ram M R, Shaw P. Clinical and conceptual comments on "Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis". *The Journal of infection* **2020**; 81(4): 647-79.
6. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nature reviews Immunology* **2020**; 20(6): 355-62.
7. Zhand S, Saghaeian Jazi M, Mohammadi S, et al. COVID-19: The Immune Responses and Clinical Therapy Candidates. *International journal of molecular sciences* **2020**; 21(15): 5559.

8. Kenneth ER, Monty M, David AS, et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI insight **2021**; 5(17).
9. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell (Cambridge) **2020**; 181(5): 1036-45.e9.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet (British edition) **2020**; 395(10223): 497-506.
11. Karaba SM, Jones G, Helsel T, et al. Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open forum infectious diseases **2021**; 8(1): ofaa578-ofaa.
12. Regidor P-A, Santos FG, Rizo JM, Egea FM. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. Medical hypotheses **2020**; 145: 110340-.
13. Panigrahy D, Gilligan MM, Huang S, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer and metastasis reviews **2020**; 39(2): 337-40.
14. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Frontiers in immunology **2020**; 11: 1708-.
15. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. The Journal of clinical investigation **2018**; 128(7): 2657-69.

16. Basil MC, Levy BD. Specialized pro-resolving mediators: endogenous regulators of infection and inflammation. *Nature reviews Immunology* **2016**; 16(1): 51-67.
17. Ramon S, Baker SF, Sahler JM, et al. The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? *The Journal of immunology (1950)* **2014**; 193(12): 6031-40.
18. Ramon S, Gao F, Serhan CN, Phipps RP. Specialized proresolving mediators enhance human B cell differentiation to antibody-secreting cells. *The Journal of immunology (1950)* **2012**; 189(2): 1036-42.
19. Tam Vincent C, Quehenberger O, Oshansky Christine M, et al. Lipidomic Profiling of Influenza Infection Identifies Mediators that Induce and Resolve Inflammation. *Cell (Cambridge)* **2013**; 154(1): 213-27.
20. Romashko M, Schragenheim J, Abraham NG, McClung JA. Epoxyeicosatrienoic Acid as Therapy for Diabetic and Ischemic Cardiomyopathy. *Trends in pharmacological sciences (Regular ed)* **2016**; 37(11): 945-62.
21. Dong L, Dong L, Zhou Y, et al. Soluble Epoxide Hydrolase Inhibitor Suppresses the Expression of Triggering Receptor Expressed on Myeloid Cells-1 by Inhibiting NF-kB Activation in Murine Macrophage. *Inflammation* **2017**; 40(1): 13-20.
22. Bora I, Steven LJ, Arzu U, et al. Soluble Epoxide Hydrolase and Epoxyeicosatrienoic Acids Modulate Two Distinct Analgesic Pathways. *Proceedings of the National Academy of Sciences - PNAS* **2008**; 105(48): 18901-6.

23. Darwesh AM, Bassiouni W, Sosnowski D, Seubert JM. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? Pharmacology & therapeutics (Oxford) **2020**: 107703-.
24. Tighe PJ, Urbanowicz RA, Fairclough CL, et al. **2020**.
25. consortium TC-GUC-U. An integrated national scale SARS-CoV-2 genomic surveillance network. The Lancet Microbe **2020**; 1(3): e99-e100.
26. Gohir SA, Greenhaff P, Abhishek A, Valdes AM. Evaluating the efficacy of Internet-Based Exercise programme Aimed at Treating knee Osteoarthritis (iBEAT-OA) in the community: a study protocol for a randomised controlled trial. BMJ open **2019**; 9(10): e030564-e.
27. Wong A, Sagar DR, Ortori CA, Kendall DA, Chapman V, Barrett DA. Simultaneous tissue profiling of eicosanoid and endocannabinoid lipid families in a rat model of osteoarthritis. Journal of lipid research **2014**; 55(9): 1902-13.
28. Chong J, Xia J. Using MetaboAnalyst 4.0 for Metabolomics Data Analysis, Interpretation, and Integration with Other Omics Data. Computational Methods and Data Analysis for Metabolomics **2020**; 2104: 337-60.
29. Norris PC, Skulas-Ray AC, Riley I, et al. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Scientific reports **2018**; 8(1): 18050-13.
30. Abdelmagid SA, Clarke SE, Nielsen DE, et al. Correction: Comprehensive profiling of plasma fatty acid concentrations in young healthy Canadian adults. PloS one **2015**; 10(5): e0128167-e.

31. Gilroy DW, Bishop-Bailey D. Lipid mediators in immune regulation and resolution. *British journal of pharmacology* **2019**; 176(8): 1009-23.
32. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. *American Journal of Physiology: Cell Physiology* **2014**; 307(1): C39-C54.
33. Koenis DS, Beegun I, Jouvène CC, et al. Disrupted Resolution Mechanisms Favor Altered Phagocyte Responses in Covid-19. *Circulation research* **2021**.
34. Archambault AS, Zaid Y, Rakotoarivelo V, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. *The FASEB journal* **2021**; 35(6): e21666-n/a.
35. Schwarz B, Sharma L, Roberts L, et al. Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome resulting in dysregulation of eicosanoid immune mediators. *medRxiv* **2020**.
36. Sandhaus S, Swick AG. Specialized proresolving mediators in infection and lung injury. *BioFactors (Oxford)* **2021**; 47(1): 6-18.
37. Recchiuti A, Patrino S, Mattoscio D, et al. Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages. *The FASEB journal* **2021**; 35(4): e21441-n/a.
38. Barden A, Phillips M, Hill LM, et al. Antiemetic doses of dexamethasone and their effects on immune cell populations and plasma mediators of inflammation resolution in healthy volunteers. *Prostaglandins, leukotrienes and essential fatty acids* **2018**; 139: 31-9.
39. Pyrillou K, Chairakaki A-D, Tamvakopoulos C, Andreacos E. Dexamethasone induces ω 3-derived immunoresolvents driving resolution

of allergic airway inflammation. Journal of allergy and clinical immunology
2018; 142(2): 691-5.e4.

40. Pal A, Gowdy KM, Oestreich KJ, Beck M, Shaikh SR. Obesity-Driven Deficiencies of Specialized Pro-resolving Mediators May Drive Adverse Outcomes During SARS-CoV-2 Infection. Frontiers in immunology **2020**; 11: 1997.

Figure Legends:

Figure 1. A: Partial least square discrimination analysis (PLS-DA) for the 44 serum lipids quantified in SARS-CoV-2(n=50) and age and sex matched controls (n=94) with $R^2 = 0.944$, $Q^2 = 0.932$ and Accuracy = 1.0 B-I: Histograms of the highest ranked lipid mediators, PUFA (AA, LA, EPA, DHA), SPMs (17-HDHA, RvD4, LXA4, LXA5), PGD2, HETEs (5-HETE, 9-HETE, 16-HETE, 19-HETE, 15-HETE), DiHETEs (5, 15-DiHETEs, 8, 9-DiHETEs), 11,12-EET, DHETs (11, 12-DHET, 14, 15-DHET) and Endocannabinoids (2-AG, AEA).

Figure 2 Serum concentrations of (A) DHA, (B) 17-HDHA, (C) RvD4 (D) Maresin 2, and (E) 18-HEPE in SARS-CoV-2 (n=50) and age and sex matched control serum (n=94) stratified by age group. Groups were assessed for normal distribution using D'Agostino & Pearson test. Significance was assessed using Kruskal-Wallis test correcting for multiple comparisons using Dunn's test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Figure 3. Correlation analysis of DHA & EPA and relevant down-stream SPM pathway metabolites (A) 17-HDHA, (B) 14-HDHA, and (C) 18-HEPE in SARS-CoV-2 (n=50) and age and sex controls (n=94). Data analysed by Spearman's Rho.

Figure 4. Correlation analysis between AA and down-stream CYP450 metabolites (A) 5,6-EET, (B) 8,9-EET, (C) 1,12-EET, and (D) 14,15-EET in SARS-CoV-2 and control groups. Data analysed by Spearman's Rho.

Figure 5. Serum concentration of significantly altered pro-resolution lipid mediators A) EPA, B) 18-HEPE, C) DHA, D) 17-HDHA, E) 14-HDHA, F) RvD4, G) Maresin 2, & H) 14,15-EET based on the anti-spike antibody response (low group <0.5 , $n=26$, (high group >0.5 , $n=24$) in SARS-CoV-2 patients. Groups were assessed for normal distribution using D'Agostino & Pearson test. Significance was assessed using Mann-Whitney test. $*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$.

Table 1. Concentrations of pro-inflammatory and anti-inflammatory bioactive lipids quantified in SARS-CoV-2 (n=50) and age and sex matched controls (n=94). Statistical analysis by Mann-Whitney Test. Where lipids were not detected in samples, an arbitrary value of 0.001 indicated by * was used for statistical analysis.

Bioactive lipids			Mean Concentration (nM) ± SD						P Value
			Control (n=94)			Sars-COV-2 (n=50)			
AA	Pro-inflammatory	μM (±SD)	47.98	±	12.75	99.61	±	60.21	<0.0001
LA			307.8	±	109.7	213.79	±	108.4	<0.001
5-HETE		nM (±SD)	0.99	±	0.40	158.33	±	159.17	<0.0001
8-HETE			0.81	±	0.57	3.52	±	3.32	<0.0001
9-HETE			0.15	±	0.05	16.27	±	19.02	<0.0001
11-HETE			1.77	±	1.34	19.84	±	19.95	<0.0001
12-HETE			0.001*			162.41	±	137.29	<0.0001
15-HETE			7.14	±	4.79	135.18	±	125.42	<0.0001
16-HETE			0.20	±	0.05	0.22	±	0.08	0.4442
19-HETE			0.37	±	0.29	188.65	±	199.17	<0.0001
20-HETE			1.04	±	0.56	69.80	±	54.66	<0.0001
TBXB2			21.66	±	20.33	63.20	±	80.40	<0.0001
11-dihy-TBXB2			1.10	±	1.47	0.29	±	0.33	0.0001
PGE2			0.37	±	0.33	0.56	±	0.41	0.0033
PGD2			0.001*			1.12	±	1.34	<0.0001
LTB4			0.52	±	0.72	5.30	±	0.67	<0.0001
13-oxo-ODE			6.82	±	5.45	25.85	±	32.33	0.0001
9-oxo-ODE			0.85	±	0.96	7.51	±	10.28	<0.0001
9-HODE			6.14	±	3.03	225.74	±	308.14	<0.0001
13-HODE			12.44	±	5.72	263.98	±	363.04	<0.0001
DHA	Anti-inflammatory	μM (±SD)	36.96	±	17.63	39.67	±	27.01	0.7135
EPA			37.26	±	4.72	26.13	±	21.59	<0.001
17-HDHA		nM (±SD)	1.88	±	1.46	88.61	±	107.3	<0.0001
14-HDHA			55.53	±	54.4	93.11	±	69.82	0.0006
18-HEPE			0.49	±	0.32	10.27	±	14.16	<0.0001
RvD4			0.001*			4.11	±	3.94	<0.0001
Maresin 2			0.03	±	0.01	0.42	±	0.48	<0.0001
5,6-EET			0.24	±	0.38	0.30	±	0.29	<0.0001
5,6-DHET	0.38	±	0.21	2.35	±	1.73	<0.0001		

5,6-Ratio			0.60	±	0.72	0.21	±	0.24	<0.0001
8,9-EET			0.21	±	0.21	0.74	±	0.88	<0.0001
8,9-DHET			0.22	±	0.07	0.47	±	0.32	<0.0001
8,9-Ratio			0.97	±	0.86	2.63	±	4.09	0.0098
11,12-EET			0.56	±	0.77	160.95	±	122.47	<0.0001
11,12-DHET			0.53	±	0.16	0.60	±	0.32	0.315
11,12-Ratio			1.09	±	1.31	363.01	±	407.70	<0.0001
14,15-EET			0.27	±	0.35	0.43	±	0.44	<0.0001
14,15-DHET			0.43	±	0.14	0.52	±	0.27	0.0672
14,15-Ratio			0.68	±	0.74	0.90	±	0.73	0.0002

559

560

Table 2. Correlation analysis between concentrations of bioactive lipid with anti-nucleocapsid & anti-spike antibody response in SARS-CoV-2 (n=50). Data analysed by Spearman's Rho.

Bioactive lipids	Correlation Analysis of Lipids vs Antibody binding			
	Anti-Nucleocapsid		Anti-Spike	
	R Value	P Value	R Value	P Value
AA	0.326	0.021	0.352	0.012
LA	0.249	0.081	0.382	0.006
DHA	0.369	0.009	0.337	0.017
EPA	0.419	0.002	0.540	<0.0001
17-HDHA	0.269	0.059	0.537	<0.0001
18-HEPE	0.366	0.009	0.410	0.003
14-HDHA	0.434	0.002	0.293	0.039
RvD4	0.211	0.142	0.449	0.001
Maresin 2	0.282	0.055	0.343	0.018
LXA4	0.051	0.723	0.324	0.022
LXA5	0.222	0.133	0.436	0.002
5-HETE	0.093	0.52	0.361	0.010
8-HETE	0.404	0.004	0.419	0.002
9-HETE	0.27	0.058	0.469	0.001
11-HETE	0.279	0.05	0.464	0.001
12-HETE	0.231	0.106	0.084	0.563
15-HETE	0.259	0.069	0.407	0.003
16-HETE	0.245	0.097	0.045	0.756
19-HETE	0.138	0.344	0.314	0.028
20-HETE	0.234	0.101	0.099	0.494
TBxB2	-0.26	0.071	-0.052	0.722
PGE2	0.049	0.744	0.275	0.056
PGD2	0.113	0.445	0.283	0.052
LTB4	-0.041	0.776	0.326	0.021
5,6-EET	0.357	0.011	0.271	0.057
5,6-DHET	0.024	0.867	0.310	0.029
5,6-Ratio	0.243	0.089	-0.018	0.904
8,9-EET	0.099	0.494	0.185	0.198
8,9-DHET	0.063	0.663	-0.104	0.474
8,9-Ratio	0.064	0.664	0.164	0.257
11,12-EET	0.239	0.093	0.084	0.564
11,12-DHET	0.109	0.452	-0.041	0.779
11,12-Ratio	0.15	0.297	0.114	0.431
14,15-EET	0.302	0.033	0.334	0.018
14,15-DHET	0.023	0.874	-0.194	0.178
14,15-Ratio	0.339	0.016	0.443	0.001
13-oxo-ODE	0.202	0.169	0.447	0.002
9-oxo-ODE	0.243	0.154	0.482	0.003
9-HODE	0.265	0.063	0.505	0.0002
13-HODE	0.268	0.059	0.488	0.0003
AEA	0.017	0.907	-0.216	0.131
PEA	-0.071	0.626	-0.083	0.567
OEA	0.063	0.666	-0.060	0.679

566 Figure 1.

568 Figure 2.

570 Figure 3.

572 Figure 4.

574 Figure 5.